Accordingly, specific cellular fluorescence confirmed panitumumab-IRDye800 delivery across leaky blood–tumor barrier, whereas intact BBB in normal brain tissue ensured minimal antibody delivery despite substantial EGFR expression, resulting in improved fluorescent tumor contrast consistent with prior preclinical (17) and clinical (2,18,19) evidence that even modest EGFR expression was sufficient for HGG detection with panitumumab-IRDye800. This evidence concerns the gene EGFR and neoplasm.